Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ABT-089

Known as: A-87089.0, ABT 089, ABYT 089 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

pozanicline

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease.
Levodopa-induced dyskinesias (LIDs) are a serious complication of levodopa therapy for Parkinson's disease for which there is… Expand
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Cholinergic Control over Attention in Rats Prone to Attribute Incentive Salience to Reward Cues
Some rats [sign-trackers (STs)] are especially prone to attribute incentive salience to reward cues, relative to others [goal… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Glutamatergic Contributions to Nicotinic Acetylcholine Receptor Agonist-Evoked Cholinergic Transients in the Prefrontal Cortex
Because modulation of cortical cholinergic neurotransmission has been hypothesized to represent a necessary mechanism mediating… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2007
Review
2007
Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition.
Attention deficit/hyperactivity disorder (ADHD) is the most commonly diagnosed neurobehavioral disorder in children and… Expand
Is this relevant?
Highly Cited
2006
Highly Cited
2006
ABT-089, A Neuronal Nicotinic Receptor Partial Agonist, for the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Pilot Study
BACKGROUND This pilot study was designed to evaluate ABT-089, a neuronal nicotinic receptor partial agonist, as treatment for… Expand
Is this relevant?
Review
2004
Review
2004
ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders.
ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride salt] is a selective neuronal nicotinic receptor (NNR… Expand
Is this relevant?
1998
1998
Central nicotinic receptor agonists ABT-418, ABT-089, and (–)-nicotine reduce distractibility in adult monkeys
Abstract Increased distractibility is associated with both Alzheimer’s disease and attention deficit disorder. The present study… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
1998
Highly Cited
1998
Activation and inhibition of the human α7 nicotinic acetylcholine receptor by agonists
To better understand the effects of weak as well as strong agonists at the human alpha7 nicotinic acetylcholine receptor (human… Expand
Is this relevant?
1997
1997
ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys.
ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride], a novel ligand at neuronal nicotinic acetylcholine… Expand
  • table 1
  • figure 2
  • figure 1
  • figure 3
  • table 2
Is this relevant?
1997
1997
ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties.
Accumulating preclinical and clinical evidence data suggests that compounds that selectively activate neuronal nicotinic… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE